文献速递甲状腺疾病

甲状腺癌患者的管理:肺叶切除术候选者的选择与管理

Approach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

过去十年,甲状腺肺叶切除术作为分化型甲状腺癌的治疗方法日益普及,主要由于低风险癌症诊断增加及证据显示低风险疾病中放射性碘无益。多项研究证实肺叶切除术是有效且安全的选择,其优于全甲状腺切除术的优势包括并发症率更低和终身左甲状腺素(LT4)治疗需求减少。近期研究拓宽了肺叶切除术的适应证,扩展至对侧良性结节及若干「不良」组织学特征(如微小甲状腺外侵犯、小淋巴结转移或多灶性——前提是这些特征尺寸极小)的患者。

要点

  • 肺叶切除术是低至低-中风险分化型甲状腺癌的首选治疗,并发症率更低且LT4需求减少。
  • 对侧良性结节及微小甲状腺外侵犯、小淋巴结转移或多灶性(尺寸极小时)可考虑肺叶切除术。
  • 微小浸润性滤泡状甲状腺癌应仅行肺叶切除术;血管侵犯时转移风险随血管数(>2-3支)、肿瘤大小和年龄增加。

核心结论

  • 肺叶切除术是许多(若非多数)低至低-中风险分化型甲状腺癌患者的首选治疗选择,提供更低的并发症率、减少的LT4治疗需求和优异的长期结局。

研究设计与样本

  • 原文未报告

主要发现

  • 多项研究证实肺叶切除术是有效且安全的选择,其优于全甲状腺切除术的优势包括并发症率更低和终身LT4治疗需求减少。
  • 近期研究拓宽了肺叶切除术的适应证,扩展至对侧良性结节及若干「不良」组织学特征(如微小甲状腺外侵犯、小淋巴结转移或多灶性——前提是这些特征尺寸极小)的患者。
  • 对于滤泡状甲状腺癌患者(通常因Bethesda III-IV细胞学接受手术),微小浸润性疾病应仅行肺叶切除术。
  • 在血管侵犯患者中,转移风险随受累血管数(>2-3支)、较大肿瘤尺寸和晚期患者年龄而增加。
  • 术后当前证据支持TSH目标在正常范围内,将LT4治疗需求降至仅30%患者;随访基于颈部超声,因为甲状腺球蛋白水平在检测复发方面价值有限。

关键数值与推荐

  • 术后TSH目标为正常范围。
  • LT4治疗需求降至仅30%患者。
  • 血管侵犯时转移风险随血管数>2-3支、较大肿瘤尺寸和晚期患者年龄增加。

临床怎么用

  • 肺叶切除术是许多低至低-中风险分化型甲状腺癌患者的首选治疗选择。
  • 对侧良性结节及微小甲状腺外侵犯、小淋巴结转移或多灶性(尺寸极小时)可考虑肺叶切除术。
  • 微小浸润性滤泡状甲状腺癌应仅行肺叶切除术。
  • 术后TSH目标为正常范围,仅30%患者需LT4治疗;随访基于颈部超声。
  • 需要进一步治疗时,完成甲状腺切除术与 upfront 全甲状腺切除术一样安全。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thyroid lobectomy has gained increasing popularity over the past decade as a treatment for differentiated thyroid cancer, largely due to a rise in the diagnosis of low-risk cancers and evidence showing no benefit from radioiodine in low-risk disease. Multiple studies have confirmed lobectomy as an effective and safe option. Its advantages over total thyroidectomy include lower complication rates and a reduced need for lifelong levothyroxine (LT4) therapy. Recent research has broadened the indications for lobectomy, extending its use to patients with contralateral benign nodules and several "adverse" histological features, such as minimal extrathyroidal extension, small lymph node metastases, or multifocality-provided these are of minimal size. For patients with follicular thyroid carcinoma, who typically undergo surgery for Bethesda III-IV cytology, minimally invasive disease should be treated with lobectomy alone. In patients with angioinvasion, the risk of metastasis increases with the number of vessels involved (>2-3 vessels), larger tumor size, and advanced patient age. Following surgery, current evidence supports a TSH target within the normal range, reducing the need for LT4 treatment to only 30% of patients. Follow-up is based on neck ultrasound because thyroglobulin levels have limited value in detecting recurrence. In cases where further treatment is required, completion thyroidectomy is as safe as upfront total thyroidectomy. Overall, lobectomy is the preferred treatment option for many, if not most, differentiated thyroid cancer patients with low to low-intermediate risk disease, offering lower complication rates, reduced need for LT4 therapy, and excellent long-term outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Robenshtok E, Bachar G, Ritter A, et al. Approach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy. J Clin Endocrinol Metab. 2025. PMID: 39745824. doi:10.1210/clinem/dgae903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。